Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 2/20 | 0.33 |
| ▸ | GNRHR | P30968 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29583203 | 1.00 | BACE1 (0.35) | BACE1MAPK1KDM5AGNRHRCYP2D6 | |
| SCHEMBL29243488 | 0.93 | MAPK1 (0.39) | BACE1MAPK1KDM5AGNRHRCYP2D6 | |
| SCHEMBL25090915 | 0.93 | MAPK1 (0.39) | BACE1MAPK1KDM5AGNRHRCYP2D6 | |
| SCHEMBL25090914 | 0.93 | MAPK1 (0.39) | BACE1MAPK1KDM5AGNRHRCYP2D6 | |
| SCHEMBL29585608 | 0.93 | MAPK1 (0.39) | BACE1MAPK1KDM5AGNRHRCYP2D6 | |
| SCHEMBL24424783 | 0.91 | BACE1 (0.34) | BACE1MAPK1KDM5AGNRHRCYP2D6 | |
| SCHEMBL29243373 | 0.91 | BACE1 (0.34) | BACE1MAPK1KDM5AGNRHRCYP2D6 | |
| SCHEMBL24424784 | 0.91 | BACE1 (0.34) | BACE1MAPK1KDM5AGNRHRCYP2D6 | |
| SCHEMBL24424115 | 0.90 | KDM5A (0.34) | BACE1MAPK1KDM5AGNRHRCYP2D6 | |
| SCHEMBL24424120 | 0.90 | KDM5A (0.34) | BACE1MAPK1KDM5AGNRHRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
| WO-2022099144-A1 | ΡΡΑRγ MODULATORS AND METHODS OF USE | Eisai R&D Mangement Co., Ltd. (JP) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | PPARG, PPARA, PPARD | BACE1 4429/4885MAPK1 1659/4885KDM5A 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.